Skip to main content
RAPT Therapeutics, Inc. logo

RAPT Therapeutics, Inc. — Investor Relations & Filings

Ticker · RAPT ISIN · US75382E1091 LEI · 549300MB473BIU78ES48 US Manufacturing
Open in API
Filings indexed 534 across all filing types
Latest filing 2026-03-18 Regulatory Filings
Country US United States of America
Listing US RAPT

About RAPT Therapeutics, Inc.

https://rapt.com/

RAPT Therapeutics, Inc. is a clinical-stage, immunology-based biopharmaceutical company focused on discovering, developing, and commercializing novel therapies for patients with inflammatory and immunologic diseases. The company's scientific approach involves developing therapeutics that intelligently target key drivers of the immune system. Its pipeline includes ozureprubart (RPT904), a long-acting anti-IgE antibody being evaluated in a Phase 2b clinical trial for the treatment of food allergies.

Recent filings

Filing Released Lang Actions
15-12G - RAPT Therapeutics, Inc. (0001673772) (Filer)
Regulatory Filings Classification · 100% confidence The document is a Form 15 filed with the SEC, which is a certification and notice of termination of registration under Section 12(g) of the Securities Exchange Act of 1934. It indicates the company is terminating or suspending its duty to file reports. The document is short (2275 characters) and is a regulatory filing notifying the SEC and public of this status change. It is not a financial report, earnings release, or management discussion. It is a formal regulatory notice related to compliance and registration status, fitting the category of Regulatory Filings (RNS).
2026-03-18 English
8-K - RAPT THERAPEUTICS, INC. (0001673772) (Filer)
M&A Activity Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated March 3, 2026, reporting the completion of a merger transaction involving RAPT Therapeutics, Inc. It details the tender offer, merger completion, changes in control, changes in directors and officers, amendments to the certificate of incorporation and bylaws, and delisting notification. The document is a current report on material events rather than a full annual or quarterly financial report. It includes information about changes in control and management, as well as delisting announcements. The primary focus is on the merger completion and related corporate changes, which aligns with the category of M&A Activity (TAR). However, since it is a Form 8-K reporting the completion of a merger and related corporate events, and not a merger proxy statement or tender offer filing, the best fitting category is M&A Activity (TAR). The document is detailed and substantive, not a brief announcement or certification, so it is not Regulatory Filings (RNS) or Report Publication Announcement (RPA).
2026-03-03 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-17 English
SCHEDULE 13G/A Filing
Major Shareholding Notification
2026-02-13 English
SCHEDULE 13G - RAPT Therapeutics, Inc. (0001673772) (Subject)
Major Shareholding Notification
2026-02-09 English
4 Filing
Director's Dealing
2026-02-02 English

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.